LIVN LivaNova PLC
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1639691 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.7%
TTM net income YoY190.1%
TTM EPS YoY187.7%
Revenue 3-yr CAGR10.5%
Net income 3-yr CAGR308.9%
Margins
Gross margin67.8%
Operating margin10.7%
Net margin13.0%
FCF margin8.6%
EBITDA margin13.0%
Returns
ROE15.5%
ROA7.4%
ROIC (approx.)15.8%
Asset turnover0.57x
Leverage & solvency
Liabilities / assets49.4%
Debt / equity0.22x
Current ratio1.46x
Interest coverage4.73x
Cash quality & payout
Operating cash flow / net income1.21x
Accruals ratio-1.6%
Payout ratio—
Capex / revenue7.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.39B | $1.25B | $1.15B | $1.02B | $1.04B |
| Cost of revenue | $448.18M | $399.95M | $397.73M | $314.58M | $329.37M |
| Gross profit | $939.87M | $853.48M | $755.82M | $707.23M | $705.99M |
| R&D expense | $185.76M | $182.51M | $193.82M | $155.81M | $183.41M |
| SG&A expense | $548.81M | $508.88M | $502.70M | $469.24M | $471.90M |
| Operating income | $199.39M | $129.05M | -$68.50M | -$76.75M | -$784,000 |
| Interest expense | $49.29M | $63.07M | $58.85M | $48.25M | $50.15M |
| Pretax income | -$220.78M | $88.31M | -$81.23M | -$75.14M | -$124.47M |
| Income tax | $21.64M | $25.06M | -$98.88M | $11.05M | $11.20M |
| Net income | -$242.47M | $63.23M | $17.55M | -$86.25M | -$135.82M |
| EBITDA | $227.95M | $154.16M | -$43.76M | -$54.38M | $23.75M |
| EPS (basic) | -4.45 | 1.17 | 0.33 | -1.61 | -2.68 |
| EPS (diluted) | -4.45 | 1.16 | 0.32 | -1.61 | -2.68 |
| Weighted avg. shares (diluted) | 54.55M | 54.57M | 54.21M | 53.47M | 50.63M |
| Balance sheet | |||||
| Cash & equivalents | $635.55M | $723.56M | $266.50M | $515.62M | $207.99M |
| Receivables | $215.99M | $193.16M | $215.07M | $183.11M | $185.35M |
| Inventory | $164.70M | $147.57M | $147.89M | $129.38M | $105.84M |
| Current assets | $1.10B | $1.13B | $988.16M | $886.14M | $679.18M |
| PP&E, net | $242.60M | $170.26M | $154.18M | $147.19M | $150.07M |
| Goodwill | $792.84M | $750.01M | $782.94M | $768.79M | $899.52M |
| Intangibles | $229.96M | $237.29M | $261.18M | $368.56M | $399.68M |
| Total assets | $2.61B | $2.51B | $2.43B | $2.29B | $2.20B |
| Current liabilities | $808.07M | $392.12M | $334.98M | $297.40M | $696.97M |
| Short-term debt | $31.47M | $78.00M | $18.11M | $23.43M | $229.67M |
| Long-term debt | $345.19M | $549.62M | $568.54M | $518.07M | $9.85M |
| Total debt | $376.66M | $627.63M | $586.65M | $541.50M | $239.52M |
| Total liabilities | $1.41B | $1.19B | $1.15B | $1.09B | $906.31M |
| Shareholders' equity | $1.20B | $1.32B | $1.28B | $1.21B | $1.29B |
| Net debt | -$258.89M | -$95.93M | $320.15M | $25.88M | $31.53M |
| Shares outstanding | 54.65M | 54.35M | 53.92M | 53.56M | 53.26M |
| Cash flow statement | |||||
| Operating cash flow | $254.34M | $183.04M | $74.91M | $69.92M | $102.54M |
| Capital expenditure | $81.05M | $47.11M | $34.98M | $26.52M | $25.48M |
| Free cash flow | $173.29M | $135.93M | $39.93M | $43.40M | $77.07M |
| Investing cash flow | -$72.91M | -$48.16M | -$40.33M | -$38.41M | $36.90M |
| Financing cash flow | -$285.66M | $18.55M | $21.48M | $280.13M | -$181.48M |
| Depreciation & amortization | $28.56M | $25.10M | $24.74M | $22.37M | $24.54M |
| Stock-based compensation | $36.29M | $33.93M | $36.35M | $44.81M | $40.56M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.